Predictive analytics on multidimensional patient data will enable personalized precision medicine in the management of cardiometabolic disease to prevent catastrophic patient outcomes.
Deliver clinically actionable solutions in clinical decision support and patient management that healthcare providers and ecosystem stakeholders will use to change patient trajectories and improve outcomes
Dr Andrew Wu is a health technology innovator and start up leader with more than 20 years experience in commercialising biomedical technologies. He is the Co-Founder and CEO of Mesh Bio, a Southeast Asia’s leading deep healthtech startup focused on providing predictive analytics solutions based on foundational digital twin models, for chronic disease diagnosis and management.
Andrew was previously COO of Clearbridge Biomedics (now known as Biolidics) developing innovative liquid biopsy cancer diagnostics. He was also Chief Product Officer of Clearbridge Health. Prior to Clearbridge, Andrew was technical director for stem cell banking laboratories across Southeast Asia. He started his career as a bioprocess engineer in the biotech CDMO industry.
Andrew holds a Bachelors and PhD in Biochemical Engineering from University College London.
Arsen Batagov is a researcher and start-up leader with more than 17 years of experience. He established the Gene Diagnostics facility at the Russian Research Institute of Cardiology in 2003. In 2009, Arsen moved to Singapore and joined A*STAR institute, where he delved into diverse aspects of bioinformatics and systems biology of cancers.
His expertise led him to assume the role of Bioinformatics Director at Vishuo Biomedical Ltd, a leading biotechnology company in Singapore, before co-founding Mesh Bio.
Arsen holds a Bachelor's and Master's degree in Genetics from St Petersburg State University, and pursued postgraduate studies in Biochemical Engineering from University College London.
